OraSure Receives Global Fund Classification to Enable HIV Self-Test Procurement
01 3월 2017 - 8:00PM
OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care
diagnostic tests and specimen collection devices, today announced
that its OraQuick® HIV Self-Test has been designated as eligible
for procurement by purchasing entities entitled to access Global
Fund and/or UNITAID resources.
The OraQuick® HIV Self-Test has been classified
by the Global Fund’s Expert Review Panel for Diagnostics as
CATEGORY-2. The classification facilitates product procurement for
12 months with Global Fund and/or UNITAID resources. During this
period, OraSure is expected to pursue and obtain WHO (World Health
Organization) pre-qualification of the product or approval from
another stringent regulatory agency.
“We are pleased to have received the endorsement
of the Global Fund’s Expert Panel,” said Douglas A. Michels,
President and CEO of OraSure Technologies. “The classification
enables government organizations implementing HIV self-test pilots
and programs to access funding for the OraQuick® HIV Self-Test.
We expect the OraQuick® HIV Self-Test to be a valuable tool
in reducing HIV infection rates globally. The Global Fund’s
action allows for the procurement of our test while we pursue WHO
prequalification.”
About the Global Fund and
UNITAID
The Global Fund is a partnership between
governments, civil society, the private sector and people affected
by diseases. The partnership organization is designed to finance
programs aimed at accelerating the end of HIV/AIDS, tuberculosis
and malaria as epidemics. For more information, please visit
http://www.theglobalfund.org.
UNITAID is engaged in finding new ways to prevent, treat and
diagnose HIV/AIDS, tuberculosis and malaria. UNITAID identifies
promising health solutions and invests in them to establish their
viability in support of widespread adoption and impact. For more
information, please visit http://www.unitaid.com.
About OraSure Technologies
OraSure Technologies is a leader in the
development, manufacture and distribution of point of care
diagnostic and collection devices and other technologies designed
to detect or diagnose critical medical conditions. Its
first-to-market, innovative products include rapid tests for the
detection of antibodies to HIV and HCV on the OraQuick® platform,
oral fluid sample collection, stabilization and preparation
products for molecular diagnostic applications, and oral fluid
laboratory tests for detecting various drugs of abuse. OraSure's
portfolio of products is sold globally to various clinical
laboratories, hospitals, clinics, community-based organizations and
other public health organizations, research and academic
institutions, distributors, government agencies, physicians'
offices, commercial and industrial entities and consumers. The
Company's products enable healthcare providers to deliver critical
information to patients, empowering them to make decisions to
improve and protect their health.
For more information on OraSure Technologies,
please visit www.orasure.com.
Company contact:
Ronald H. Spair
Chief Financial Officer
610-882-1820
Investorinfo@orasure.com
www.orasure.com
Media contact:
Shauna White
Corporate Marketing Manager
484-353-1575
media@orasure.com
www.orasure.com
OraSure Technologies (NASDAQ:OSUR)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
OraSure Technologies (NASDAQ:OSUR)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024